Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 1.00 |
| ▸ | MAOB | P27338 | 7/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19384016 | 1.00 | KDM1A (1.00) | KDM1AMAOB | |
| SCHEMBL20656957 | 0.86 | KDM1A (0.75) | KDM1AMAOB | |
| SCHEMBL19383925 | 0.86 | KDM1A (0.75) | KDM1AMAOB | |
| SCHEMBL20656833 | 0.85 | KDM1A (0.73) | KDM1AMAOB | |
| SCHEMBL20664066 | 0.85 | KDM1A (0.73) | KDM1AMAOB | |
| SCHEMBL19383928 | 0.85 | KDM1A (0.73) | KDM1AMAOB | |
| SCHEMBL20656813 | 0.84 | KDM1A (0.72) | KDM1AMAOB | |
| SCHEMBL19383904 | 0.84 | KDM1A (0.72) | KDM1AMAOB | |
| SCHEMBL19383892 | 0.84 | KDM1A (1.00) | KDM1AMAOB | |
| SCHEMBL19383935 | 0.84 | KDM1A (1.00) | KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-17 | — | — | US | claimed |
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-04 | — | — | US | claimed |
| EP-3431471-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USERS THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-01-23 | — | — | EP | claimed |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-17 | — | — | US | disclosed |
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-04 | — | — | US | disclosed |
| EP-3431471-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USERS THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SETDB1, KDM1B, SETD7 | KDM1A 4/4885MAOB 323/4885 |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SETDB1, KDM1B, SETD7 | KDM1A 4/4885MAOB 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.